$EPIX
ESSA Pharma Inc

2020 Q4 Form 10-K Financial Statement

#000155837020014403 Filed on December 15, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $2.210M $2.130M $1.210M
YoY Change 3.27% 76.03% -0.82%
% of Gross Profit
Research & Development $4.486M $2.170M $2.040M
YoY Change 73.39% 6.37% 77.39%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $6.696M $4.430M $3.240M
YoY Change 35.49% 36.73% 36.71%
Operating Profit -$4.430M
YoY Change
Interest Expense $130.0K -$130.0K -$80.00K
YoY Change 160.0% 62.5% -42.86%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$6.564M -$4.560M -$3.310M
YoY Change 34.2% 37.76% 45.81%
Income Tax -$35.15K -$10.00K $0.00
% Of Pretax Income
Net Earnings -$6.529M -$4.550M -$3.310M
YoY Change 41.52% 37.46% 45.18%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$195.9K -$163.3K -$221.8K
COMMON SHARES
Basic Shares Outstanding 33.60M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $74.50M $78.30M $53.30M
YoY Change 62.31% 46.9% 260.14%
Cash & Equivalents $52.48M $56.32M $53.32M
Short-Term Investments $22.00M $22.00M $0.00
Other Short-Term Assets $1.100M $1.700M $600.0K
YoY Change 120.0% 183.33% 20.0%
Inventory
Prepaid Expenses $1.138M $1.600M $615.5K
Receivables $200.0K $300.0K $400.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $75.90M $80.30M $54.30M
YoY Change 62.17% 47.88% 248.07%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $300.0K $300.0K $300.0K
YoY Change 0.0% 0.0% 50.0%
Total Long-Term Assets $277.6K $277.6K $274.1K
YoY Change -53.73% 1.3% -31.48%
TOTAL ASSETS
Total Short-Term Assets $75.90M $80.30M $54.30M
Total Long-Term Assets $277.6K $277.6K $274.1K
Total Assets $76.17M $80.57M $54.57M
YoY Change 60.71% 47.65% 241.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.376M $678.6K $1.359M
YoY Change 25.07% -50.05% 171.71%
Accrued Expenses $609.7K $310.6K $151.2K
YoY Change 509.71% 105.45%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $3.709M
YoY Change -100.0% 32.46%
Total Short-Term Liabilities $2.035M $1.203M $5.575M
YoY Change 69.61% -78.41% 68.93%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00 $100.0K $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $100.0K $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.035M $1.203M $5.575M
Total Long-Term Liabilities $0.00 $100.0K $0.00
Total Liabilities $2.074M $1.331M $5.591M
YoY Change 59.51% -76.2% -18.97%
SHAREHOLDERS EQUITY
Retained Earnings -$87.50M -$80.97M -$57.52M
YoY Change 40.76%
Common Stock $134.4M $131.1M $78.55M
YoY Change 66.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $74.10M $79.24M $48.98M
YoY Change
Total Liabilities & Shareholders Equity $76.17M $80.57M $54.57M
YoY Change 60.71% 47.65% 241.08%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$6.529M -$4.550M -$3.310M
YoY Change 41.52% 37.46% 45.18%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$3.943M -$4.430M -$5.150M
YoY Change 17.32% -13.98% 129.91%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$21.74M $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 -$21.74M $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 150.9K 46.05M 53.60M
YoY Change -103.74% -14.09% -6800.0%
NET CHANGE
Cash From Operating Activities -3.943M -4.430M -5.150M
Cash From Investing Activities 0.000 -21.74M 0.000
Cash From Financing Activities 150.9K 46.05M 53.60M
Net Change In Cash -3.836M 19.88M 48.45M
YoY Change -48.08% -58.97% -1595.37%
FREE CASH FLOW
Cash From Operating Activities -$3.943M -$4.430M -$5.150M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001633932
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32064411
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20762374
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
001-37410
CY2020 dei Entity Registrant Name
EntityRegistrantName
ESSA Pharma Inc.
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A1
CY2020 dei Entity Address Country
EntityAddressCountry
CA
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2569713
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
Suite 720
CY2020 dei Entity Address Address Line2
EntityAddressAddressLine2
999 West Broadway
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Vancouver
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
BC
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
V5Z 1K5
CY2020 dei City Area Code
CityAreaCode
778
CY2020 dei Local Phone Number
LocalPhoneNumber
331-0962
CY2020 dei Security12b Title
Security12bTitle
Common Shares
CY2020 dei Trading Symbol
TradingSymbol
EPIX
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020Q1 dei Entity Public Float
EntityPublicFloat
83300000
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
33600122
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56320763
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53322723
CY2020Q3 us-gaap Short Term Investments
ShortTermInvestments
22011337
CY2019Q3 us-gaap Short Term Investments
ShortTermInvestments
0
CY2020Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
309538
CY2019Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
360800
CY2020Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1600128
CY2019Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
615485
CY2020Q3 epix Operating Lease Right Of Use Assets Current
OperatingLeaseRightOfUseAssetsCurrent
55162
CY2019Q3 epix Operating Lease Right Of Use Assets Current
OperatingLeaseRightOfUseAssetsCurrent
0
CY2020Q3 us-gaap Assets Current
AssetsCurrent
80296928
CY2019Q3 us-gaap Assets Current
AssetsCurrent
54299008
CY2020Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
277637
CY2019Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
274085
CY2020Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
0
CY2019Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
300000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1203324
CY2019Q3 us-gaap Liabilities
Liabilities
5591264
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.04
CY2020Q3 us-gaap Assets
Assets
80574565
CY2019Q3 us-gaap Assets
Assets
54573093
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1144230
CY2019Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1565789
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
59094
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2020Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2019Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
3708955
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5574744
CY2020Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
127376
CY2019Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
16520
CY2020Q3 us-gaap Liabilities
Liabilities
1330700
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32064411
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20762374
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
131086364
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
78545108
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
31204284
CY2019Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
30038134
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2076479
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2076479
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80970304
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57524934
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
79243865
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
48981829
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
80574565
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
54573093
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12145968
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6696234
CY2020 epix Financing Costs
FinancingCosts
618109
CY2019 epix Financing Costs
FinancingCosts
602744
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11373952
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5455189
CY2020 us-gaap Operating Expenses
OperatingExpenses
24138029
CY2019 us-gaap Operating Expenses
OperatingExpenses
12754167
CY2020 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-44851
CY2019 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
7845
CY2020 us-gaap Interest Income Deposits With Financial Institutions
InterestIncomeDepositsWithFinancialInstitutions
559719
CY2019 us-gaap Interest Income Deposits With Financial Institutions
InterestIncomeDepositsWithFinancialInstitutions
26251
CY2020 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-110856
CY2019 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1159
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23734017
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12718912
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-288647
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
37920
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-23445370
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-12756832
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.51
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22443893
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8433441
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-23445370
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-12756832
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
110324
CY2019 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
0
CY2020 us-gaap Accretion Expense
AccretionExpense
12992
CY2019 us-gaap Accretion Expense
AccretionExpense
0
CY2020 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-110856
CY2019 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1159
CY2020 epix Income Tax Expense Operating Activities
IncomeTaxExpenseOperatingActivities
-280000
CY2019 epix Income Tax Expense Operating Activities
IncomeTaxExpenseOperatingActivities
0
CY2020 epix Finance Expense Operating Activities
FinanceExpenseOperatingActivities
211079
CY2019 epix Finance Expense Operating Activities
FinanceExpenseOperatingActivities
602744
CY2020 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-13059
CY2019 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-16457
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
7522608
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
1146707
CY2020 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-89938
CY2019 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
59665
CY2020 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1262280
CY2019 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
179416
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-46358
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1014049
CY2020 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-20000
CY2019 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-4722
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16983152
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12249935
CY2020 us-gaap Proceeds From Other Deposits
ProceedsFromOtherDeposits
274085
CY2019 us-gaap Proceeds From Other Deposits
ProceedsFromOtherDeposits
201399
CY2020 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
22011337
CY2019 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21737252
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
201399
CY2020 epix Cash Acquisition From Acquisition Of Business
CashAcquisitionFromAcquisitionOfBusiness
0
CY2019 epix Cash Acquisition From Acquisition Of Business
CashAcquisitionFromAcquisitionOfBusiness
22244248
CY2020 us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
64804
CY2019 us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
1860341
CY2020 epix Payment Of Sublease Termination Costs
PaymentOfSubleaseTerminationCosts
0
CY2019 epix Payment Of Sublease Termination Costs
PaymentOfSubleaseTerminationCosts
246906
CY2020 epix Operating Lease Payments Financing Activities
OperatingLeasePaymentsFinancingActivities
119384
CY2019 epix Operating Lease Payments Financing Activities
OperatingLeasePaymentsFinancingActivities
0
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48990000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
36000000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3447954
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2362329
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
915
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
257172
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
80714
CY2019 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
0
CY2020 us-gaap Repayments Of Debt
RepaymentsOfDebt
3199799
CY2019 us-gaap Repayments Of Debt
RepaymentsOfDebt
2808823
CY2020 epix Repayments Of Final Payment Of Debt
RepaymentsOfFinalPaymentOfDebt
688000
CY2019 epix Repayments Of Final Payment Of Debt
RepaymentsOfFinalPaymentOfDebt
0
CY2020 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
32235
CY2019 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
401929
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
41776625
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
50563920
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-58181
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-21805
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2998040
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
38493579
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53322723
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14829144
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56320763
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53322723
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
8935013
CY2019 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
20247296
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
36000000
CY2019 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
4591425
CY2019 epix Prefunded Warrant Exercised Value
PrefundedWarrantExercisedValue
1070
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1146707
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-12756832
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
48981829
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
48990000
CY2020 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3144003
CY2020 epix Prefunded Warrant Exercised Value
PrefundedWarrantExercisedValue
257172
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
915
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
80714
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7522608
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-23445370
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
79243865
CY2020 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.     NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Nature of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ESSA Pharma Inc. (the “Company”) was incorporated under the laws of the Province of British Columbia on January 6, 2009. The Company’s head office address is Suite 720 – 999 West Broadway, Vancouver, BC, V5Z 1K5. The registered and records office address is the 26<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Floor at 595 Burrard Street, Three Bentall Centre, Vancouver, BC, V7X 1L3. The Company is listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “EPIX”. On October 30, 2020 the Company’s common shares delisted in Canada from the TSX Venture Exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is focused on the development of small molecule drugs for the treatment of prostate cancer. The Company has acquired a license to certain patents (the “NTD Technology”) which were the joint property of the British Columbia Cancer Agency and the University of British Columbia. As at September 30, 2020, no products are in commercial production or use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Acquisition of Realm Therapeutics plc</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On July 31, 2019, the Company acquired all of the issued and outstanding shares of Realm Therapeutics plc (“Realm”) pursuant to a Scheme of Arrangement as sanctioned on July 29, 2019 by the High Court of Justice in England and Wales (the “Realm Acquisition”) (Note 4).</p>
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the derivative liabilities, the valuation of equity instruments issued for services, income taxes and the product development and relocation grant. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both. Significant assumptions about the future and other sources of estimation uncertainty that management has made at the statement of financial position date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions that have been made, relate to the following key estimates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Income tax</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The determination of income tax is inherently complex and requires making certain estimates and assumptions about future events. Changes in facts and circumstances as a result of income tax audits, reassessments, changes to corporate structure and associated domiciling, jurisprudence and any new legislation may result in an increase or decrease the provision for income taxes. The value of deferred tax assets is evaluated based on the probability of realization; the Company has assessed that it is improbable that such assets will be realized and has accordingly not recognized a value for deferred taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Derivative financial instruments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Certain warrants are treated as derivative financial liabilities. The estimated fair value, based on the Black-Scholes model, is adjusted on a quarterly basis with gains or losses recognized in the statement of loss and comprehensive loss. The Black-Scholes model is based on significant assumptions such as volatility, dividend yield, expected term and liquidity discounts (Note 10).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Share-based payments and compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company has applied estimates with respect to the valuation of shares issued for non-cash consideration. Shares are valued at the fair value of the equity instruments granted at the date the Company receives the goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the fair value of the underlying common shares, the expected life of the share option, volatility and dividend yield and making assumptions about them. The assumptions and models used for estimating fair value for share-based payment transactions are discussed in Note 11.</p>
CY2020Q3 us-gaap Prepaid Insurance
PrepaidInsurance
825014
CY2019Q3 us-gaap Prepaid Insurance
PrepaidInsurance
524257
CY2020Q3 epix Prepaid Preclinical And Clinical Expenses And Deposits
PrepaidPreclinicalAndClinicalExpensesAndDeposits
650586
CY2019Q3 epix Prepaid Preclinical And Clinical Expenses And Deposits
PrepaidPreclinicalAndClinicalExpensesAndDeposits
8260
CY2020Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
124528
CY2019Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
82968
CY2020Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1600128
CY2019Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
615485
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
678643
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1358554
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
310604
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
151182
CY2020Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
154983
CY2019Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
56053
CY2018Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1144230
CY2019Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1565789
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
110324
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
55162
CY2020 epix Operating Lease Liabilities Accretion Expenses
OperatingLeaseLiabilitiesAccretionExpenses
12992
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
119384
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
59094
CY2020Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.120
CY2020Q3 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P6M
CY2019 epix Class Of Warrant Or Right Weighted Average Exercise Price Warrants Granted
ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsGranted
0.0001
CY2019 epix Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
2188999
CY2019 epix Class Of Warrant Or Right Weighted Average Exercise Price Warrants Exercised
ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised
-0.002
CY2019 epix Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
1250
CY2019 epix Class Of Warrant Or Right Weighted Average Exercise Price Warrants Expired
ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired
-31.17
CY2019Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
12393092
CY2019Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.31
CY2020 epix Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
3120115
CY2018Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
17679
CY2019 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
1159
CY2019Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
16520
CY2020 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-110856
CY2020Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
127376
CY2020Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2020Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
127376
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
900459
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.88
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
255000
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.77
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
32998
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.10
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1122461
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.59
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4218000
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.31
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
416
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.20
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
30461
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
28.46
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5309584
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.42
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1859826
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.52
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5309584
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M17D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4218000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
255000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.31
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.00
CY2018Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2663937
CY2018Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.13
CY2019 epix Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
11919404
CY2020 epix Class Of Warrant Or Right Weighted Average Exercise Price Warrants Exercised
ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised
-0.08
CY2020Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9272977
CY2020Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.73
CY2020 epix Income Tax Reconciliation Financing Costs
IncomeTaxReconciliationFinancingCosts
-849000
CY2019 epix Income Tax Reconciliation Financing Costs
IncomeTaxReconciliationFinancingCosts
-720000
CY2020 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
1013353
CY2019 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
457920
CY2020 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
-307000
CY2019 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
-196000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4210000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3354000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-288647
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
37920
CY2017Q4 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.26
CY2018Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.27
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-288647
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
37920
CY2020Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9272977
CY2019 epix Stock Issued During Period Value Pre Funded Warrants Exercised
StockIssuedDuringPeriodValuePreFundedWarrantsExercised
1652530
CY2019 epix Pre Funded Warrants Exercised
PreFundedWarrantsExercised
1653999
CY2019 epix Business Combination Transaction Cost Through Accounts Payable And Accrued Liability
BusinessCombinationTransactionCostThroughAccountsPayableAndAccruedLiability
64804
CY2019 epix Share Issuance Cost Through Accounts Payable And Accrued Liabilities
ShareIssuanceCostThroughAccountsPayableAndAccruedLiabilities
303951
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23734017
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12718912
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-6408000
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3434000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
2031000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
227000
CY2019 epix Income Tax Reconciliation Taxable Capital Gains
IncomeTaxReconciliationTaxableCapitalGains
346000
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
21000
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
3000
CY2020Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
21297000
CY2019Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
17306000
CY2020Q3 epix Deferred Tax Assets Equipment And Intangible Assets
DeferredTaxAssetsEquipmentAndIntangibleAssets
77000
CY2019Q3 epix Deferred Tax Assets Equipment And Intangible Assets
DeferredTaxAssetsEquipmentAndIntangibleAssets
77000
CY2020Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
39000
CY2019Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
137000
CY2020Q3 epix Deferred Tax Assets Financing Costs
DeferredTaxAssetsFinancingCosts
1462000
CY2019Q3 epix Deferred Tax Assets Financing Costs
DeferredTaxAssetsFinancingCosts
1159000
CY2020Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
22875000
CY2019Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
18679000
CY2020Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
22875000
CY2019Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
18679000
CY2020Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2019Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q3 epix Working Capital
WorkingCapital
79093604
CY2020 epix Percentage Of Change In Foreign Exchange Rate
PercentageOfChangeInForeignExchangeRate
0.10

Files In Submission

Name View Source Status
0001558370-20-014403-index-headers.html Edgar Link pending
0001558370-20-014403-index.html Edgar Link pending
0001558370-20-014403.txt Edgar Link pending
0001558370-20-014403-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20200930.xsd Edgar Link pending
tmb-20200930x10k.htm Edgar Link pending
tmb-20200930x10k001.jpg Edgar Link pending
tmb-20200930x10k002.jpg Edgar Link pending
tmb-20200930x10k_htm.xml Edgar Link completed
tmb-20200930xex21d1.htm Edgar Link pending
tmb-20200930xex23d1.htm Edgar Link pending
tmb-20200930xex23d1001.jpg Edgar Link pending
tmb-20200930xex23d1002.jpg Edgar Link pending
tmb-20200930xex31d1.htm Edgar Link pending
tmb-20200930xex31d2.htm Edgar Link pending
tmb-20200930xex32d1.htm Edgar Link pending
tmb-20200930xex4d2.htm Edgar Link pending
tmb-20200930_cal.xml Edgar Link unprocessable
tmb-20200930_def.xml Edgar Link unprocessable
tmb-20200930_lab.xml Edgar Link unprocessable
tmb-20200930_pre.xml Edgar Link unprocessable